BIOMAT Database Logo BIOMAT Database Logo

The growing evidence for targeting P-glycoprotein in lysosomes to overcome resistance. 2020

Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Molecular Pharmacology & Pathology Program, Department of Pathology & Bosch Institute, The University of Sydney, Sydney, NSW 2006, Australia.

UI MeSH Term Description Entries
D008247 Lysosomes A class of morphologically heterogeneous cytoplasmic particles in animal and plant tissues characterized by their content of hydrolytic enzymes and the structure-linked latency of these enzymes. The intracellular functions of lysosomes depend on their lytic potential. The single unit membrane of the lysosome acts as a barrier between the enzymes enclosed in the lysosome and the external substrate. The activity of the enzymes contained in lysosomes is limited or nil unless the vesicle in which they are enclosed is ruptured or undergoes MEMBRANE FUSION. (From Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed). Autolysosome,Autolysosomes,Lysosome
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013882 Thiosemicarbazones Thiosemicarbazone
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug
D020168 ATP Binding Cassette Transporter, Subfamily B, Member 1 A 170-kDa transmembrane glycoprotein from the superfamily of ATP-BINDING CASSETTE TRANSPORTERS. It serves as an ATP-dependent efflux pump for a variety of chemicals, including many ANTINEOPLASTIC AGENTS. Overexpression of this glycoprotein is associated with multidrug resistance (see DRUG RESISTANCE, MULTIPLE). ATP-Dependent Translocase ABCB1,MDR1 Protein,MDR1B Protein,Multidrug Resistance Protein 1,P-Glycoprotein,P-Glycoprotein 1,ABCB1 Protein,ATP Binding Cassette Transporter, Sub-Family B, Member 1,ATP-Binding Cassette, Sub-Family B, Member 1,CD243 Antigen,PGY-1 Protein,1, P-Glycoprotein,ABCB1, ATP-Dependent Translocase,ATP Dependent Translocase ABCB1,Antigen, CD243,P Glycoprotein,P Glycoprotein 1,PGY 1 Protein,Protein, MDR1B,Translocase ABCB1, ATP-Dependent

Related Publications

Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp).
January 2021, Medicinal research reviews,
Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Novel Pt(IV) complexes to overcome multidrug resistance in gastric cancer by targeting P-glycoprotein.
October 2021, European journal of medicinal chemistry,
Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance.
January 2021, Nature communications,
Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review.
September 2023, Pharmacology & therapeutics,
Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.
September 2016, Expert opinion on drug metabolism & toxicology,
Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance.
January 2008, Current medicinal chemistry,
Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Multimodal Nanoplatform with ROS Amplification to Overcome Multidrug Resistance in Prostate Cancer via Targeting P-Glycoprotein and Ferroptosis.
January 2024, Advanced healthcare materials,
Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer.
February 2022, Nanomedicine : nanotechnology, biology, and medicine,
Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Novel modulators to overcome P-glycoprotein-mediated multidrug resistance in tumor cells.
November 2004, International journal of clinical pharmacology and therapeutics,
Sven Marcel Stefan, and Patric J Jansson, and Danuta S Kalinowski, and Rukhsana Anjum, and Mahendiran Dharmasivam, and Des R Richardson
Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma.
December 2018, Molecular cancer therapeutics,
Copied contents to your clipboard!